PE20071092A1 - Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico - Google Patents

Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico

Info

Publication number
PE20071092A1
PE20071092A1 PE2006001558A PE2006001558A PE20071092A1 PE 20071092 A1 PE20071092 A1 PE 20071092A1 PE 2006001558 A PE2006001558 A PE 2006001558A PE 2006001558 A PE2006001558 A PE 2006001558A PE 20071092 A1 PE20071092 A1 PE 20071092A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
methyl
antagonist
composition including
chlorophenyl
Prior art date
Application number
PE2006001558A
Other languages
English (en)
Inventor
Marck Black
Beth Borowsky
Nancy Rogacki
Yaw Senyah
Rachel Stevens
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of PE20071092A1 publication Critical patent/PE20071092A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNO O MAS ANTAGONISTAS DEL RECEPTOR CB1 DE FORMULA (I) EN DONDE R ES CR1R2, C=C(R5)SO2R6 O C=C(R7)SO2ALQ; R1 ES H Y R2 ES -C(R8)(R9)(R10), -C(R8)(R11)(R12), ENTRE OTROS; O R1 ES ALQUILO, NH-R15, CN, -S-ALQ-NR16R17-, ENTRE OTROS Y R2 ES -C(R8)(R11)(R12); R3 Y R4 SON INDEPENDIENTEMENTE ALQUILO, CICLOALQUILO, O AROMATICOS TALES COMO FENILO, NAFTILO O INDENILO, OPCIONALEMTE SUSTITUIDOS ENTRE OTROS. SON SELECCIONADOS: (RS)-1-[BIS(4-CLOROFENIL)METIL)]-3-[(3,5-DIFLUOROFENIL)(METILSULFONIL)METIL]AZETIDINA, N-{1-[BIS(4-CLOROFENIL)METIL)]-AZETIDIN-3-IL}-N-(PIRID-3-IL)METILSULFONAMIDA, ENTRE OTROS. EN COMBINACION CON B) UNO O MAS AGENTES ANTISICOTICOS SELECCIONADOS DE OLANZAPINA, CLOZAPINA, HALOPERIDOL, SUCCINATO DE LOXAPINA, ENTRE OTROS. DICHA COMPOSICION ES UTIL PARA TRATAR LOS EFECTOS SECUNDARIOS Y SINTOMAS NEGATIVOS DE LA ESQUIZOFRENIA
PE2006001558A 2005-12-08 2006-12-06 Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico PE20071092A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74843405P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
PE20071092A1 true PE20071092A1 (es) 2007-12-10

Family

ID=37964962

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001558A PE20071092A1 (es) 2005-12-08 2006-12-06 Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico

Country Status (23)

Country Link
US (1) US20080221078A1 (es)
EP (1) EP1962834A2 (es)
JP (1) JP2009518423A (es)
KR (1) KR20080073737A (es)
CN (1) CN101321523A (es)
AR (1) AR056846A1 (es)
AU (1) AU2006321907A1 (es)
BR (1) BRPI0619541A2 (es)
CA (1) CA2632673A1 (es)
CR (1) CR9957A (es)
DO (1) DOP2006000273A (es)
EC (1) ECSP088505A (es)
IL (1) IL191888A0 (es)
MA (1) MA30090B1 (es)
NO (1) NO20082923L (es)
PE (1) PE20071092A1 (es)
RU (1) RU2008127491A (es)
SV (1) SV2008002929A (es)
TN (1) TNSN08205A1 (es)
TW (1) TW200803839A (es)
UY (1) UY29995A1 (es)
WO (1) WO2007067617A2 (es)
ZA (1) ZA200803924B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
JP2010540629A (ja) * 2007-10-04 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション カルシウムチャネル遮断薬としての置換アリールスルホン誘導体
AR069700A1 (es) 2007-12-18 2010-02-10 Sanofi Aventis Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros.
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
AU2015301891B2 (en) 2014-08-11 2019-12-05 Angion Biomedica Corporation Cytochrome P450 inhibitors and uses thereof
WO2016109492A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp Methods and agents for treating disease
CN109923102B (zh) 2016-08-24 2022-11-15 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗功能下降的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
BRPI0411131A (pt) * 2003-06-11 2006-07-18 Merck & Co Inc composto, método de tratar uma doença mediada pelo receptor de canabinóide 1, método de previnir a obesidade de uma pessoa com risco de obesidade, composição, e, uso de um composto
CA2537535A1 (en) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Novel medical use of selective cb1-receptor antagonists
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Also Published As

Publication number Publication date
DOP2006000273A (es) 2007-10-15
JP2009518423A (ja) 2009-05-07
UY29995A1 (es) 2007-07-31
IL191888A0 (en) 2009-08-03
AR056846A1 (es) 2007-10-24
RU2008127491A (ru) 2010-01-20
WO2007067617A3 (en) 2007-11-01
AU2006321907A1 (en) 2007-06-14
CR9957A (es) 2008-09-22
ZA200803924B (en) 2009-10-28
BRPI0619541A2 (pt) 2011-10-04
MA30090B1 (fr) 2008-12-01
TW200803839A (en) 2008-01-16
CA2632673A1 (en) 2007-06-14
KR20080073737A (ko) 2008-08-11
NO20082923L (no) 2008-09-02
WO2007067617A2 (en) 2007-06-14
ECSP088505A (es) 2008-08-29
EP1962834A2 (en) 2008-09-03
US20080221078A1 (en) 2008-09-11
TNSN08205A1 (en) 2009-10-30
SV2008002929A (es) 2009-12-02
CN101321523A (zh) 2008-12-10

Similar Documents

Publication Publication Date Title
PE20071092A1 (es) Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
BRPI0612888B8 (pt) anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
ATE433454T1 (de) Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors
SV2005002099A (es) " nuevos compuestos " ref. pc 32096a
PE20141681A1 (es) Inhibidores de btk
PE20081374A1 (es) Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
AR002971A1 (es) COMPUESTOS DE 3-(1,2,3,6)-TETRAHIDROPIRIDIN-4-ILO Y 3-PIPERIDIN-4-ILO-1H- INDOL, AGONISTAS DE 5HT(1f) FORMULACIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA ACTIVAR DICHOS RECEPTORES 5HT(1f) Y/O PARA TRATAR LAS MIGRANAS Y DESORDENES ASOCIADOS CON ELLA.
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
ECSP099371A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
PE20121084A1 (es) Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
MXPA06014470A (es) Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas.
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
AR063073A1 (es) Inhibidor de la activacion de stat 3/5
PE20080007A1 (es) Compuestos derivados de bencimidazolona que tienen actividad en el receptor m1
AR054688A1 (es) Alquil-piridinas como inhibidores 11-beta de la diabetes
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
GT200900026A (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
PE20091433A1 (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177
MX2007003119A (es) Nuevas amidas heterociclicas.
PE20070830A1 (es) Composiciones que comprenden una combinacion de antagonistas ccr5 y de cxcr4
PE20090112A1 (es) Derivados de indol como agonistas del receptor de canabinoides cb1

Legal Events

Date Code Title Description
FC Refusal